- Home
- SJT vs MOLN Comparison
SJT vs MOLN Comparison
Compare SJT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- MOLN
- Stock Information
- Founded
- SJT 1980
- MOLN 2004
- Country
- SJT United States
- MOLN Switzerland
- Employees
- SJT N/A
- MOLN N/A
- Industry
- SJT Oil & Gas Production
- MOLN
- Sector
- SJT Energy
- MOLN
- Exchange
- SJT Nasdaq
- MOLN Nasdaq
- Market Cap
- SJT 212.1M
- MOLN 195.4M
- IPO Year
- SJT N/A
- MOLN 2021
- Fundamental
- Price
- SJT $4.44
- MOLN $5.56
- Analyst Decision
- SJT
- MOLN
- Analyst Count
- SJT 0
- MOLN 0
- Target Price
- SJT N/A
- MOLN N/A
- AVG Volume (30 Days)
- SJT 311.6K
- MOLN 7.1K
- Earning Date
- SJT 11-14-2024
- MOLN 03-13-2025
- Dividend Yield
- SJT 2.49%
- MOLN N/A
- EPS Growth
- SJT N/A
- MOLN N/A
- EPS
- SJT 0.19
- MOLN N/A
- Revenue
- SJT $11,031,594.00
- MOLN $7,105,397.00
- Revenue This Year
- SJT N/A
- MOLN N/A
- Revenue Next Year
- SJT N/A
- MOLN $29.41
- P/E Ratio
- SJT $23.54
- MOLN N/A
- Revenue Growth
- SJT N/A
- MOLN N/A
- 52 Week Low
- SJT $3.21
- MOLN $3.32
- 52 Week High
- SJT $5.81
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- SJT 58.04
- MOLN 53.39
- Support Level
- SJT $4.36
- MOLN $4.98
- Resistance Level
- SJT $4.81
- MOLN $5.91
- Average True Range (ATR)
- SJT 0.23
- MOLN 0.27
- MACD
- SJT 0.06
- MOLN 0.08
- Stochastic Oscillator
- SJT 67.83
- MOLN 69.45
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.